0001209191-21-058530.txt : 20211001 0001209191-21-058530.hdr.sgml : 20211001 20211001171642 ACCESSION NUMBER: 0001209191-21-058530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210901 FILED AS OF DATE: 20211001 DATE AS OF CHANGE: 20211001 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galante Joseph C CENTRAL INDEX KEY: 0001632384 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 211299957 MAIL ADDRESS: STREET 1: 111 TENTH AVENUE STREET 2: SUITE 200 CITY: NASHVILLE STATE: TN ZIP: 37203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-01 0 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001632384 Galante Joseph C 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203 1 0 0 0 Common Stock 2021-09-01 4 P 0 142 2.88 A 37955 D Common Stock 2021-09-02 4 P 0 142 2.88 A 38097 D Common Stock 2021-09-03 4 P 0 142 2.85 A 38239 D Common Stock 2021-09-07 4 P 0 142 2.79 A 38381 D Common Stock 2021-09-08 4 P 0 142 2.89 A 38523 D Common Stock 2021-09-09 4 P 0 142 2.77 A 38665 D Common Stock 2021-09-10 4 P 0 142 2.78 A 38807 D Common Stock 2021-09-13 4 P 0 142 2.96 A 38949 D Common Stock 2021-09-14 4 P 0 142 3.02 A 39091 D Common Stock 2021-09-15 4 P 0 142 2.86 A 39233 D Common Stock 2021-09-16 4 P 0 142 2.91 A 39375 D Common Stock 2021-09-17 4 P 0 142 2.85 A 39517 D Common Stock 2021-09-20 4 P 0 142 2.82 A 39659 D Common Stock 2021-09-21 4 P 0 142 2.81 A 39801 D Common Stock 2021-09-22 4 P 0 142 2.76 A 39943 D Common Stock 2021-09-23 4 P 0 142 2.75 A 40085 D Common Stock 2021-09-24 4 P 0 142 2.74 A 40227 D Common Stock 2021-09-27 4 P 0 142 2.79 A 40369 D Common Stock 2021-09-28 4 P 0 142 2.76 A 40511 D Common Stock 2021-09-29 4 P 0 142 2.82 A 40653 D Common Stock 2021-09-30 4 P 0 142 2.72 A 40795 D The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. Joseph C. Galante by /s/ John Hamm as attorney-in-fact 2021-10-01